Regeneron and Sanofi’s Dupixent bags fifth drug label in Japan

Regeneron and Sanofi's Dupixent has been approved for the treatment of chronic spontaneous urticaria (CSU) or itching in Japan.

Feb 16, 2024 - 18:00

Regeneron and Sanofi’s Dupixent bags fifth drug label in Japan

Regeneron and Sanofi's Dupixent has been approved for the treatment of chronic spontaneous urticaria (CSU) or itching in Japan.

Read the original article

Tags:

Previous Article

QBiotics wins FDA orphan status for rainforest-derived cancer drug

Dragonfly and Gilead enter partnership for cancer therapy

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

ASCO 2023: Research backs chemo-only approach for some rectal cancer patients

ASCO 2023: Research backs chemo-only approach for some ...

Jun 5, 2023

invIOs’s cell therapy secures Austrian Government grant for Phase Ib trial

invIOs’s cell therapy secures Austrian Government grant...

Sep 5, 2023

Cataract drugs in development, 2023

Nov 30, 2023